Table 2.
Cell therapy clinical trials for erectile dysfunction after prostatectomy.
| Study | Number of patients | Time after prostatectomy | Type of cells | Evaluation tools | Administration method | Administered cells | Patients with reported improvement (%) |
|---|---|---|---|---|---|---|---|
| Yiou et al. (78) | 12 | 6 mths to 3 yr | BM-MNC | IIEF-15 EHS Doppler US |
Intracavernous injection | 2 × 107; 2 × 108 1 × 109; 2 × 109 |
12 (100%) |
| Yiou et al. (79) | 12 | 6 mths to 3 yr | BM-MNC | IIEF-15 EHS Doppler US |
Intracavernous injection | 1 × 109 | 12 (100%) |
| Haahr et al. (80) | 17 | 5–18 mths | ADRC | IIEF-5 EHS |
Intracavernous injection | 9 × 106 | 8 (47%) |
BM-MNC, Bone-marrow derived mononuclear cell; ADRCs, Adipose-derived regenerative cells; IIEF-15, International Index of Erectile Function-15; EHS, Erectile Hardness Score; IIEF-15, International Index of Erectile Function-5.